title: Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.
abstract: Several studies have examined the link between the cannabinoid CB1 receptor and several neuropsychiatric illnesses, including schizophrenia. As such, there is a need for in vivo imaging tracers so that the relationship between CB1 and schizophrenia (SZ) can be further studied. In this paper, we present our first human studies in both healthy control patients and patients with schizophrenia using the novel PET tracer, [(11)C]OMAR (JHU75528), we have shown its utility as a tracer for imaging human CB1 receptors and to investigate normal aging and the differences in the cannabinoid system of healthy controls versus patients with schizophrenia. A total of ten healthy controls and nine patients with schizophrenia were included and studied with high specific activity [(11)C]OMAR. The CB1 binding (expressed as the distribution volume; V(T)) was highest in the globus pallidus and the cortex in both controls and patients with schizophrenia. Controls showed a correlation with the known distribution of CB1 and decline of [(11)C]OMAR binding with age, most significantly in the globus pallidus. Overall, we observed elevated mean binding in patients with schizophrenia across all regions studied, and this increase was statistically significant in the pons (p<0.05), by the Students t-test. When we ran a regression of the control subjects V(T) values with age and then compared the patient data to 95% prediction limits of the linear regression, three patients fell completely outside for the globus pallidus, and in all other regions there were at least 1-3 patients outside of the prediction intervals. There was no statistically significant correlations between PET measures and the individual Brief Psychiatry Rating Score (BPRS) subscores (r=0.49), but there was a significant correlation between V(T) and the ratio of the BPRS psychosis to withdrawal score in the frontal lobe (r=0.60), and middle and posterior cingulate regions (r=0.71 and r=0.79 respectively). In conclusion, we found that [(11)C] OMAR can image human CB1 receptors in normal aging and schizophrenia. In addition, our initial data in subjects with schizophrenia seem to suggest an association of elevated binding specific brain regions and symptoms of the disease.
authors.affiliation: Radiology, Johns Hopkins University, Baltimore, MD 21287, USA. dfwong@jhmi.edu
authors.forename: Dean F
authors.initials: DF
authors.lastname: Wong
authors.forename: Hiroto
authors.initials: H
authors.lastname: Kuwabara
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Horti
authors.forename: Vanessa
authors.initials: V
authors.lastname: Raymont
authors.forename: James
authors.initials: J
authors.lastname: Brasic
authors.forename: Maria
authors.initials: M
authors.lastname: Guevara
authors.forename: Weiguo
authors.initials: W
authors.lastname: Ye
authors.forename: Robert F
authors.initials: RF
authors.lastname: Dannals
authors.forename: Hayden T
authors.initials: HT
authors.lastname: Ravert
authors.forename: Ayon
authors.initials: A
authors.lastname: Nandi
authors.forename: Arman
authors.initials: A
authors.lastname: Rahmim
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Ming
authors.forename: Igor
authors.initials: I
authors.lastname: Grachev
authors.forename: Christine
authors.initials: C
authors.lastname: Roy
authors.forename: Nicola
authors.initials: N
authors.lastname: Cascella
mesh_terms: D000328:Adult; D001921:Brain / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography / Q000379:methods*; D011720:Pyrazoles / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism*; D012559:Schizophrenia / Q000000981:diagnostic imaging* / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: C515663:4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; D010880:Piperidines; D011720:Pyrazoles; D019275:Radiopharmaceuticals; D043884:Receptor, Cannabinoid, CB1
references.citation: Hum Brain Mapp. 2008 Apr;29(4):478-89
references.pmid: 17525988
references.citation: Neuropsychopharmacology. 2008 Jan;33(2):259-69
references.pmid: 17392732
references.citation: Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
references.pmid: 2308954
references.citation: Pharmacogenomics J. 2007 Aug;7(4):275-81
references.pmid: 16983399
references.citation: Addict Biol. 2008 Jun;13(2):147-59
references.pmid: 18482430
references.citation: Neuropsychopharmacology. 2004 Nov;29(11):2108-14
references.pmid: 15354183
references.citation: Psychopharmacology (Berl). 2009 Oct;206(2):313-24
references.pmid: 19652957
references.citation: J Nucl Med. 2008 Mar;49(3):439-45
references.pmid: 18287275
references.citation: J Neural Transm (Vienna). 2007;114(8):1055-63
references.pmid: 17370106
references.citation: Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):413-31
references.pmid: 19609589
references.citation: Neuroscience. 2001;103(1):9-15
references.pmid: 11311783
references.citation: Biol Psychiatry. 2005 Mar 15;57(6):594-608
references.pmid: 15780846
references.citation: Am J Epidemiol. 2002 Aug 15;156(4):319-27
references.pmid: 12181101
references.citation: Neuroimage. 2008 Feb 15;39(4):1533-41
references.pmid: 18077184
references.citation: Arch Gen Psychiatry. 2009 Feb;66(2):196-204
references.pmid: 19188542
references.citation: Arch Gen Psychiatry. 2007 May;64(5):532-42
references.pmid: 17485605
references.citation: BMJ. 2002 Nov 23;325(7374):1212-3
references.pmid: 12446537
references.citation: Lancet. 1987 Dec 26;2(8574):1483-6
references.pmid: 2892048
references.citation: Med Res Rev. 2009 Mar;29(2):213-71
references.pmid: 18777572
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9800-5
references.pmid: 17535893
references.citation: Neuroimage. 2002 Jan;15(1):273-89
references.pmid: 11771995
references.citation: Neuroimage. 2009 Nov 1;48(2):362-70
references.pmid: 19573609
references.citation: Neuroendocrinology. 2010;91(2):155-68
references.pmid: 19815998
references.citation: J Nucl Med. 2006 Oct;47(10):1689-96
references.pmid: 17015906
references.citation: Int J Neuropsychopharmacol. 2008 Sep;11(6):827-35
references.pmid: 18257959
references.citation: Neuroscience. 1997 Mar;77(2):299-318
references.pmid: 9472392
references.citation: Neuroimage. 2006 Nov 15;33(3):843-54
references.pmid: 16996751
references.citation: Phys Med Biol. 2005 Oct 21;50(20):4887-912
references.pmid: 16204879
references.citation: Arch Gen Psychiatry. 2008 Jul;65(7):772-84
references.pmid: 18606950
references.citation: Neuro Endocrinol Lett. 2009;30(2):153-79
references.pmid: 19675519
references.citation: Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):279-84
references.pmid: 18186055
references.citation: BMJ. 2002 Nov 23;325(7374):1199
references.pmid: 12446534
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2005 May;371(5):428-33
references.pmid: 15995876
references.citation: J Neurosci. 2001 Apr 1;21(7):2425-33
references.pmid: 11264316
references.citation: Eur J Neurosci. 2003 Dec;18(11):3134-44
references.pmid: 14656310
references.citation: Exp Brain Res. 2006 Jul;172(4):556-60
references.pmid: 16710682
references.citation: Trends Cogn Sci. 2000 Jun;4(6):215-222
references.pmid: 10827444
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60
references.pmid: 14751433
references.citation: BMJ. 2005 Jan 1;330(7481):11
references.pmid: 15574485
references.citation: J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
references.pmid: 2384545
references.citation: Arch Gen Psychiatry. 1992 Mar;49(3):246
references.pmid: 1567279
references.citation: Pharmacol Rev. 2002 Jun;54(2):161-202
references.pmid: 12037135
references.citation: PLoS One. 2008 Feb 20;3(2):e1640
references.pmid: 18286196
references.citation: Mol Psychiatry. 2002;7(5):515-8
references.pmid: 12082570
references.citation: Neuroreport. 1999 Jun 3;10(8):1665-9
references.pmid: 10501554
references.citation: Prog Brain Res. 2005;150:205-17
references.pmid: 16186025
references.citation: Eur J Neurosci. 2003 May;17(9):1747-54
references.pmid: 12752773
references.citation: Int Rev Neurobiol. 2007;78:289-326
references.pmid: 17349865
references.citation: Curr Pharm Des. 2008;14(31):3363-83
references.pmid: 19075713
references.citation: Psychiatry Res. 2006 Oct 30;147(2-3):249-56
references.pmid: 16919917
references.citation: Nucl Med Biol. 2000 Aug;27(6):627-30
references.pmid: 11056380
references.citation: J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
references.pmid: 17519979
references.citation: Int J Addict. 1986 Apr-May;21(4-5):579-87
references.pmid: 3021637